- Home
- CYN vs XAIR Comparison
CYN vs XAIR Comparison
Compare CYN & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYN | XAIR |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 11.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CYN | XAIR |
|---|---|---|
| Price | $1.52 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 7.2M | 1.1M |
| Earning Date | 03-04-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $457,227.00 | ★ $5,802,000.00 |
| Revenue This Year | $31.96 | $127.85 |
| Revenue Next Year | $1,459.25 | $179.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 347.74 | 147.74 |
| 52 Week Low | $1.41 | $0.67 |
| 52 Week High | $41.54 | $8.12 |
Technical Indicators
Market Signals| Indicator | CYN | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 31.23 | 41.63 |
| Support Level | $1.41 | $0.95 |
| Resistance Level | $1.74 | $1.25 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 4.44 | 11.32 |
Price Performance
Historical ComparisonAbout CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company. Its flagship innovation is DriveMod, an autonomous driving solution that can be flexibly deployed on multiple vehicle types manufactured by Original Equipment Manufacturers in various environments.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.